OPTIMA HEALTH PLAN

MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions:</u> The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; <u>fax to 1-844-668-1550</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. <u>If information provided is not complete, correct, or legible, authorization can be delayed</u>.

<u>For Medicare Members:</u> Medicare Coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: https://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx. Additional indications may be covered at the discretion of the health plan.

<u>Drug Requested</u>: Durysta[™] (bimatoprost implant) 10 mcg (J7351) (Medical)

MEMBER & PRESCRIBER INFO		
Member Name:		
Member Optima #:	I	Oate of Birth:
Prescriber Name:		
Prescriber Signature:	ture: Date:	
Office Contact Name:		
Phone Number:	Fax Number:	
DEA OR NPI #:		
DRUG INFORMATION: Authorization Drug Form/Strength:		
Dosing Schedule: Length of Therapy:		erapy:
Diagnosis:	nosis: ICD Code, if applicable:	
Weight:	Date:	
☐ Left Eye	□ Right Eye	□ Both Eyes
☐ Standard Review. In checking this box, or the member's ability to regain maxim	· ·	

Dosing Limits:

- Durysta[™] is an ophthalmic drug delivery system for a single intracameral administration, via an injection procedure, of a biodegradable implant
- Recommended Dosage: Insert 1 implant (10 mcg) in anterior chamber of affected eye. Maximum of 1 single implant per eye per lifetime. Do not readminister to an eye that has received a prior implant
- 10 mcg implant (syringe) (1.00 each) = 10 billable units

	each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be or request may be denied.
Length	of Authorization: 6 months
	Member is 18 years of age or older
□]	Prescribed by, or in consultation with, an Ophthalmologist
	Member has ONE of the following diagnoses:
[□ Open-Angle Glaucoma (OAG)
Ţ	☐ Ocular Hypertension (OHT)
	Member has no history of Corneal Endothelial Cell Dystrophy or Corneal Transplantation
1	Member has documented treatment failure, intolerance, contraindication of <u>TWO</u> ophthalmic prostaglandin analogs (e.g., bimatoprost, latanoprost, or travoprost) (verified by chart notes and/or pharmacy paid claims)
i I	Member has documented treatment failure, intolerance, contraindication of at least <u>TWO</u> ophthalmic products (either as monotherapy or as concomitant therapy) from two different pharmacological classes for the treatment of OAG or OHT (verified by chart notes and/or pharmacy paid claims):
[☐ Alpha-agonist (e.g., brimonidine)
Į.	☐ Beta-blockers (e.g., betaxolol, timolol)
Ţ	☐ Carbonic anhydrase inhibitors (e.g., brinzolamide, dorzolamide)
Į	☐ Rho kinase inhibitor (e.g., netarsudil)
	eatment of Previously Treated Eye(s). NOT COVERED. Durysta is approved for one- e in each treated eye. Repeat administration in previously treated eye(s) will NOT be approved
Medica	ation being provided by (check applicable box(es) below):
□ Ph	nysician's office OR
review v	ent reviews: Practitioner should call Optima Pre-Authorization Department if they believe a standard would subject the member to adverse health consequences. Optima's definition of urgent is a lack of nt that could seriously jeopardize the life or health of the member or the member's ability to regain function.

**Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. **

*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. *

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To

*Approved by Pharmacy and Therapeutics Committee: \(\frac{11/19/2020}{2020}\); 8/16/2023 REVISED/UPDATED: 6/47/2021; 6/15/2022; 9/7/2023